Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    63,688.94
    -749.89 (-1.16%)
     

  • CMC Crypto 200

    1,324.80
    -71.73 (-5.13%)
     

  • S&P 500

    5,110.36
    +61.94 (+1.23%)
     

  • Dow

    38,301.98
    +216.18 (+0.57%)
     

  • Nasdaq

    15,961.24
    +349.48 (+2.24%)
     

  • Gold

    2,346.00
    +3.50 (+0.15%)
     

  • Crude Oil

    83.88
    +0.31 (+0.37%)
     

  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Why Myriad Genetics (MYGN) is Poised to Beat Earnings Estimates Again

Zacks Equity Research

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Myriad Genetics Inc. (MYGN), a firm in the Drugs industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, MYGN has beaten estimates by at least 40% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, MYGN expected to earn 46 cents per share, while it actually reported earnings of 68 cents per share, a beat of 47.8%. Meanwhile, for the most recent quarter, the company looked to deliver earnings of 47 cents a share, when it actually saw earnings of 66 cents per share instead, representing a 40.4% positive surprise.

Thanks in part to this history, recent estimates have been moving higher for Myriad Genetics. In fact, the Earnings ESP for MYGN is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for MYGN, as the firm currently has a Zacks Earnings ESP of 13.04%, so another beat could be around the corner.

This is particularly true when you consider that MYGN has a great Zacks Rank #1 (Strong Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. And when you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that MYGN could see another beat at its next report, especially if recent trends are any guide.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




MYRIAD GENETICS INC (MYGN): Free Stock Analysis Report


Zacks Investment Research